Open AccessHydroxyeyhyl starch: Controversies revisited
Author(s) -
Rashmi Datta,
R. Nair,
Anil Pandey,
Narinder Kumar,
Tapan Kumar Sahoo
Publication year - 2014
Publication title -
journal of anaesthesiology-clinical pharmacology/journal of anaesthesiology clinical pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.466
H-Index - 32
eISSN - 2231-2730
pISSN - 0970-9185
DOI - 10.4103/0970-9185.142801
Subject(s) - hydroxyethyl starch , medicine , intensive care medicine , clinical trial , meta analysis , evidence based medicine , medline , scientific evidence , the internet , alternative medicine , pathology , law , epistemology , world wide web , philosophy , political science , computer science
Hydroxyethyl starch (HES) family has been one of the cornerstones in fluid management for over four decades. Recent evidence from clinical studies and meta-analyses has raised few concerns about the safety of these fluids, especially in certain subpopulations of patients. High-quality clinical trials and meta-analyses have emphasized nephrotoxic effects, increased risk of bleeding, and a trend toward higher mortality in these patients after the use of HES solutions. Scientific evidence was derived from international guidelines, aggregated research literature, and opinion-based evidence was obtained from surveys and other activities (e.g., internet postings). On critical analysis of the current data available, it can be summarized that further large scale trials are still indicated before HES can be discarded.